Business
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
-- XPOVIO® Achieves Net Product Revenue of $98.4 Million for Full Year 2021; Company Provides Full Year 2022 XPOVIO Net Product Revenue Guidance of $135 to
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"-- XPOVIO® Achieves Net Product Revenue of $98.4 Million for Full Year 2021; Company Provides Full Year 2022 XPOVIO Net Product Revenue Guidance of $135 to $145 Million --\n --Total Revenue of $209.8 Million for Full Year 2021, Including a $75 Million Up-front Payment Related to the Exclusive XPOVIO Licensing Agreement with the Menarini Group --\n -- Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer --\n -- Conference Call Scheduled for Today at 8:30 a.m. ET --\n\n\nNEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) (\"Karyopharm,\" the \"Company,\" \"we\" and \"our\"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor) and provided an overview of its key clinical development programs.\n\"I am exceptionally proud of the Karyopharm team's performance in 2021 as we advanced all aspects of our business, including securing a commercialization partnership with Menarini for Europe and other key global territories,\" said Richard Paulson, President and Chief Executive Officer of Karyopharm. \"We delivered consecutive quarters of double-digit growth driven by XPOVIO's strong commercial performance in the second half of the year and head into 2022 with momentum as we continue to prioritize driving sales and the adoption of XPOVIO in multiple myeloma. Our momentum is accelerating as we reported positive top-line data from the SIENDO study evaluating selinexor as a maintenance therapy following front-line chemotherapy in patients with advanced or recurrent endometrial cancer. Based on these findings, Karyopharm intends to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in the first half of this year. We are also progressing our pipeline in key indications of multiple myeloma, myelodysplastic syndromes and myelofibrosis to improve survival and outcomes for patients with cancer.\"\nFourth Quarter 2021 and Recent Highlights\nXPOVIO Commercial Performance\nAchieved U.S. net product reve...